Gilead Sciences Sets New 52-Week High at $108.72 (GILD)
Shares of Gilead Sciences (NASDAQ:GILD) hit a new 52-week high during mid-day trading on Tuesday , Stock Ratings Network.com reports. The company traded as high as $108.72 and last traded at $106.10, with a volume of 13,497,806 shares traded. The stock had previously closed at $107.45.
A number of analysts have recently weighed in on GILD shares. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $105.55.
The stock’s 50-day moving average is $92.9 and its 200-day moving average is $82.26. The company has a market cap of $160.6 billion and a P/E ratio of 24.34.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.00 EPS for the current fiscal year.
In other Gilead Sciences news, Director John Francis Cogan unloaded 5,000 shares of the company’s stock on the open market in a transaction dated Thursday, August 21st. The stock was sold at an average price of $101.09, for a total transaction of $505,450.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.